Email Your State Senator Today to Protect the Future of the Massachusetts Biopharma Industry
By Bob Coughlin, President & CEO, MassBio
I asked for your help a few weeks ago to fight what MassBio saw as the greatest threat to the Massachusetts biopharma industry, a proposal in the House budget to allow the state to set prices for prescription drugs covered in MassHealth (the state’s Medicaid program). Employees of the biopharma industry and others that benefit from the life sciences’ on-going success took action and sent letters to their state representatives in support of an Amendment that lessened the negative impacts of this proposal. The best part: your outreach worked. The House carefully considered the impact of the policy and adopted the compromise amendment.
We now have the same fight in the Senate and I’m asking for your help again.
The Massachusetts State Senate recently released their draft Fiscal Year 2020 Budget and it goes even further than the original House language. Outside Sections 4 and 39 would allow the state to determine an arbitrary price for a prescription drug if the drug’s manufacturer does not agree to provide “voluntary” additional discounts. If passed, this drastic approach would threaten patients’ access to the next generation of breakthrough therapies, ruin Massachusetts’ image as the best place in the world for the life sciences, and immediately threaten the continued success of one of our state’s fastest growing sectors and the industries that benefit from it.
I’m asking anyone who works for or in support of the life sciences industry to contact their State Senator TODAY about how they can fix this harmful proposal.
Visit MassBio’s website to send an email to your State Senator asking them to support Amendment #654. Passage of this Amendment will help protect patient access to new drugs and Massachusetts’ leading biotech cluster.
Take action today and help keep Massachusetts the best place in the world for bringing new therapies to patients: https://www.massbio.org/discover/take-action
- Bob Coughlin, President & CEO of MassBio